NASDAQ:EOLSEvolus Stock Price, Forecast & News

Evolus' stock was trading at $5.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EOLS stock has decreased by 47.0% and is now trading at $3.13. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Evolus.

Evolus is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Evolus.

Evolus Inc (NASDAQ:EOLS) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by $0.03. The business earned $10.50 million during the quarter, compared to analysts' expectations of $16.91 million. Evolus had a negative net margin of 217.51% and a negative return on equity of 197.30%. View Evolus' earnings history.

8 brokers have issued 1-year price objectives for Evolus' shares. Their forecasts range from $3.00 to $30.00. On average, they expect Evolus' share price to reach $11.88 in the next twelve months. This suggests a possible upside of 279.4% from the stock's current price. View analysts' price targets for Evolus.

Press coverage about EOLS stock has trended negative this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Evolus earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Evolus.

Evolus saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 5,000,000 shares, an increase of 14.7% from the June 15th total of 4,360,000 shares. Based on an average daily trading volume, of 871,900 shares, the days-to-cover ratio is presently 5.7 days. Currently, 22.8% of the company's stock are short sold. View Evolus' Current Options Chain.

Some companies that are related to Evolus include Frequency Therapeutics (FREQ), Applied Therapeutics (APLT), Homology Medicines (FIXX), Provention Bio (PRVB), ZIOPHARM Oncology (ZIOP), Passage Bio (KROS), RAPT Therapeutics (RAPT), Eagle Pharmaceuticals (EGRX), VBI Vaccines (VBIV), Radius Health (RDUS), Trillium Therapeutics (TRIL), Atreca (BCEL), Vanda Pharmaceuticals (VNDA), Cue Biopharma (CUE) and Ardelyx (ARDX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), Advanced Micro Devices (AMD), Revance Therapeutics (RVNC), Camtek (CAMT), Plug Power (PLUG), Micron Technology (MU), Canopy Growth (CGC), Tandem Diabetes Care (TNDM), Calithera Biosciences (CALA) and JD.Com (JD).

(EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EOLS stock can currently be purchased for approximately $3.13.

Evolus has a market capitalization of $105.57 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Evolus employs 70 workers across the globe.

The official website for Evolus is www.evolus.com.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]